Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.

Author: , AlmeidaLuis, ElgerChristian, HalászPeter, MaiaJoana, Soares-da-SilvaPatrício

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

ESL, 800 and 1,200 mg once-daily, was well tolerated and more effective than placebo in patients who were refractory to treatment with one or two concomitant AEDs.
Paper Details　
Original Abstract of the Article :
PURPOSE: To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in adults with >or=4 partial-onset seizures (simple or complex, with or without secondary generalization) per 4 weeks despite treatment with 1-2 antiepileptic drugs (AEDs)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1528-1167.2008.01946.x

データ提供：米国国立医学図書館（NLM）

Eslicarbazepine Acetate: A New Hope for Refractory Seizures

Refractory partial seizures, those that don't respond to conventional treatments, pose a significant challenge in epilepsy management. This study investigates the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in adults. The researchers found that ESL, particularly at higher doses, significantly reduced seizure frequency compared to placebo, demonstrating its potential as an effective treatment option for refractory seizures. The study also highlights the importance of individualized dosing to optimize treatment outcomes and minimize adverse effects.

Eslicarbazepine Acetate: A Promising Treatment for Refractory Seizures

This study provides encouraging evidence for the effectiveness of eslicarbazepine acetate in treating refractory partial seizures. The findings suggest that ESL can significantly reduce seizure frequency, offering a potential new treatment option for individuals struggling with this challenging condition. This research underscores the importance of individualized dosing and ongoing monitoring to optimize treatment outcomes and manage potential adverse effects.

Navigating the Desert of Epilepsy Treatment

The desert of epilepsy treatment can be a challenging landscape, with individuals seeking effective solutions for managing seizures. This study offers a glimmer of hope for individuals with refractory partial seizures, highlighting the potential of eslicarbazepine acetate as a promising new treatment option. It's a reminder that the journey toward effective epilepsy management requires ongoing research and a commitment to finding better solutions for those living with this condition.

Dr.Camel's Conclusion

The desert of epilepsy treatment can be a daunting landscape, but new oases of hope are emerging. This research sheds light on the potential of eslicarbazepine acetate as a promising treatment for refractory seizures, offering a ray of sunshine for those seeking relief from this challenging condition.

Date :
  1. Date Completed 2009-04-13
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

19243424

DOI: Digital Object Identifier

10.1111/j.1528-1167.2008.01946.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.